Table 2.
Unadjusted and adjusted logistic regression analyses of factors associated with DAA-based therapy uptake among PWID with chronic HCV infection (n=915), Vancouver, Canada (April 2015 – November 2017)
| Characteristic | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|
| Age (per year older) | 1.04 (1.02 – 1.06)† ‡ | 1.02 (1.00 – 1.04) |
| Male gender (yes vs. no) | 1.70 (1.16 – 2.52)† ‡ | 1.19 (0.78 – 1.84) |
| White race (yes vs. no) | 1.74 (1.21 – 2.52)† ‡ | 1.56 (1.05 – 2.35)‡ |
| HIV-positive (yes vs. no) | 2.72 (1.89 – 3.92)† ‡ | 2.29 (1.55 – 3.40)‡ |
| ≥ Daily heroin injection (yes vs. no)* | 0.41 (0.24 – 0.67)† ‡ | 0.63 (0.34 – 1.09) |
| ≥ Daily cocaine injection (yes vs. no)* | 0.61 (0.21 – 1.44) | |
| ≥ Daily crack use (yes vs. no)* | 0.46 (0.20 – 0.92)† ‡ | 0.41 (0.17 – 0.85)‡ |
| ≥ Daily opioid analgesic use (yes vs. no)* | 0.88 (0.20 – 2.63) | |
| Syringe sharing (yes vs. no)* | 0.87 (0.20 – 2.62) | |
| High-risk drinking (yes vs. no)* | 0.46 (0.24 – 0.83)† ‡ | 0.47 (0.23 – 0.88)‡ |
| In addiction care (reference: none)* | ||
| OAT | 1.22 (0.83 – 1.81) | |
| Other treatment modalities | 1.12 (0.59 – 2.05) | |
| Ever received IFN-based therapy for HCV infection | 0.80 (0.35 – 1.63) | |
| In HCV-related care (yes vs. no)* | 2.68 (1.86 – 3.89)† ‡ | 1.94 (1.31 – 2.90)‡ |
| Homelessness (yes vs. no)* | 0.43 (0.22 – 0.76)† ‡ | 0.80 (0.39 – 1.52) |
| Residency in the Downtown Eastside (yes vs. no)* | 0.59 (0.42 – 0.85)† ‡ | 0.80 (0.54 – 1.18) |
| Employment (yes vs. no)* | 1.53 (1.02 – 2.26)† ‡ | 1.47 (0.94 – 2.28) |
| Prohibited income generation (yes vs. no)* | 0.44 (0.30 – 0.65)† ‡ | 0.79 (0.51 – 1.23) |
| Incarceration (yes vs. no)* | 0.21 (0.04 – 0.70)† ‡ | 0.54 (0.08 – 1.97) |
DAA, direct-acting antiviral; OAT, opioid agonist therapy.
*
Refers to the 6-month period prior to the interview
†
p<0.10 and included in the multivariable model
‡
p<0.05